Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Anthem Biosciences IPO Date, Review, Price, Allotment Details

By Jagat Joshi
July 17, 2025

Anthem Biosciences IPO open date is July 14, 2025 and the IPO will close on July 16, 2025. Anthem Biosciences IPO is a Book Build Issue. The company to raise around ₹3,395 crores via IPO that comprises fresh issue of ₹[.] crores and offer for sale up to 5,95,61,404 equity shares with face value of ₹2 each.

Anthem Biosciences IPO price band is ₹540 to ₹570 per share. The retail quota is 35%, QIB is 50%, and HNI is 15%. Anthem Biosciences IPO to list on BSE, NSE on July 21, 2025. The allotment of Anthem Biosciences IPO date is July 17, 2025.

The company reported revenue of ₹1,930.29 crores in 2025 against ₹1,483.07 crore in 2024. The company reported profit of ₹451.26 crores in 2025 against profit of ₹367.31 crores in 2024. As per the financials the IPO investors should apply the IPO for a long term.

Anthem Biosciences IPO Details

IPO Open Date:	July 14, 2025
IPO Close Date:	July 16, 2025
Face Value:	₹2 Per Equity Share
IPO Price Band:	₹540 to ₹570 Per Share
Issue Size:	Approx ₹3,395 Crores
Offer for Sale:	Approx 5,95,61,404 Equity Shares
Issue Type:	Book Build Issue
IPO Listing:	BSE & NSE
Retail Quota:	Not more than 35%
QIB Quota:	Not more than 50%
NII Quota:	Not more than 15%
DRHP Draft Prospectus:	Click Here
RHP Draft Prospectus:	Click Here
Anchor Investors List:	Click Here

Anthem Biosciences IPO Market Lot

The Anthem Biosciences IPO minimum market lot is 26 shares with ₹14,820 application amount. The retail investors can apply up-to 13 lots with 338 shares of ₹1,92,660 amount.

Application	Lot Size	Shares	Amount
Retail Minimum	1	26	₹14,820
Retail Maximum	13	338	₹1,92,660
S-HNI Minimum	14	364	₹2,07,480
B-HNI Minimum	68	1,768	₹10,07,760

Anthem Biosciences IPO Dates

The Anthem Biosciences IPO date is July 14 and the close date is July 16. The Anthem Biosciences IPO allotment will be finalized on July 17 and the IPO listing on July 21.

IPO Open Date:	July 14, 2025
IPO Close Date:	July 16, 2025
Basis of Allotment:	July 17, 2025
Refunds:	July 18, 2025
Credit to Demat Account:	July 18, 2025
IPO Listing Date:	July 21, 2025

Promoters of Anthem Biosciences IPO

The promoters of the company are Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa and Ishaan Bhardwaj.

About Anthem Biosciences IPO

Anthem Biosciences Limited, founded in 2006, is one of the growing innovation-driven and technology-focused Contract Research, Development and Manufacturing Organizations (“CRDMO”) with end-to-end operations covering drug discovery, development, and manufacturing. Anthem Biosciences is one of the few companies in India with integrated capabilities in New Chemical Entities (NCE) and New Biological Entities (NBE) throughout drug discovery, development, and commercial manufacturing.

Anthem Biosciences is a one-stop service provider engaged in serving a wide range of customers, including emerging biotech companies and large pharmaceutical firms around the world. The company is involved in the manufacturing of specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. The company has supplied to over 150 customers, from small biotech to large pharmaceutical companies, as of March 31, 2024. Currently, the company has a team of 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, and chemical engineers.

Anthem Biosciences IPO Company Financial Report

The company reported revenue of ₹1,930.29 crores in 2025 against ₹1,483.07 crore in 2024. The company reported profit of ₹451.26 crores in 2025 against profit of ₹367.31 crores in 2024.

Amount ₹ in Crores

Period Ended	Revenue	Expense	Profit After Tax	Assets
2022	₹1,280.24	₹734.10	₹405.54	₹1,618.87
2023	₹1,133.99	₹698.50	₹385.19	₹2,014.46
2024	₹1,483.07	₹1,005.75	₹367.31	₹2,398.11
2025	₹1,930.29	₹1,273.42	₹451.26	₹2,807.58

Anthem Biosciences IPO Valuation – FY2025

Check Anthem Biosciences IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

KPI	Values
ROE:	20.82%
ROCE:	27.64%
EBITDA Margin:	36.81%
PAT Margin:	23.38%
Debt to equity ratio:	0.05
Earning Per Share (EPS):	₹8.07 (Basic)
Price/Earning P/E Ratio:	N/A
Return on Net Worth (RoNW):	20.82%
Net Asset Value (NAV):	₹43.10

Peer Group Comparison

Company	EPS	PE Ratio	RoNW %	NAV	Income
Syngene International Limited	12.35	51.54	11.05%	117.42	3,642.40 Cr.
Sai Life Sciences Limited	8.83	92.18	10.96%	102.12	1,694.57 Cr.
Suven Life Sciences Limited	10.52	97.29	13.61%	72.31	1,197.58 Cr.
Divi’s Laboratories Limited	82.53	83.22	15.35%	564.87	9,360.00 Cr.

Objects of the Issue

The Company will not receive any proceeds from the Offer (the “Offer Proceeds”) and all the Offer Proceeds will be received by the Selling Shareholders after deduction of Offer related expenses and relevant taxes thereon, to be borne by the respective Selling Shareholders.

Anthem Biosciences IPO Review

IPO Watch – May Apply
Canara Bank –
DRChoksey FinServ –
Emkay Global –
Hem Securities –
IDBI Capital –
Marwadi Shares –
Nirmal Bang –
SBICAP Securities –
Sharekhan –
SMC Global –
Sushil Finance –
Swastika Investmart –
Ventura Securities –
Geojit –
Reliance Securities –
Capital Market –
BP Wealth –
ICICIdirect –
Choice Broking –

Anthem Biosciences IPO Registrar

KFin Technologies Limited
Phone: 04067162222, 04079611000
Email: anthem.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/

IPO Lead Managers aka Merchant Bankers

Jm Financial Limited
Citigroup Global Markets India Private Limited
J.P. Morgan India Private Limited
Nomura Financial Advisory And Securities (India) Pvt Ltd

Company Address

Anthem Biosciences Limited
No. 49, F1 & F2, Canara Bank Road
Bommasandra Industrial Area, Phase 1,
Bommasandra,
Bengaluru, Karnataka, 560099
Phone: +91 080 6672 400
Email: investors.abl@anthembio.com
Website: https://www.anthembio.com/

Anthem Biosciences IPO FAQs

What is Anthem Biosciences IPO?

Anthem Biosciences IPO is a Mainboard IPO. The company is going to raise ₹3,395 Crores via IPO. The issue is priced at ₹540 to₹570 per equity share. The IPO is to be listed on BSE & NSE.

When Anthem Biosciences IPO will open for subscription?

The IPO is to open on July 14, 2025 for QIB, NII, and Retail Investors. The IPO will close on July 16, 2025.

What is Anthem Biosciences IPO Investors Portion?

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

How to Apply the Anthem Biosciences IPO?

You can apply for Anthem Biosciences IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

What is Anthem Biosciences IPO Issue Size?

Anthem Biosciences IPO issue size is ₹3,395 crores.

What is Anthem Biosciences IPO Price Band?

Anthem Biosciences IPO Price Band is ₹540 to₹570.

What is Anthem Biosciences IPO Lot Size?

The minimum bid is 26 Shares with ₹14,820 amount.

What is the Anthem Biosciences IPO Allotment Date?

Anthem Biosciences IPO allotment date is July 17, 2025.

What is the Anthem Biosciences IPO Listing Date?

Anthem Biosciences IPO listing date is July 21, 2025. The IPO is to list on BSE & NSE.

Note: The Anthem Biosciences IPO price band and date are officially announced. The (Anthem Biosciences IPO grey market premium) will be added to the IPO GMP page as it will start).

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.